Last reviewed · How we verify
NCT07509801
A Study to Evaluate the Safety and Efficacy of NT-88
NA trial testing Conventional therapeutic drugs in Heart Failure With Mildly Reduced Ejection Fraction in 60 participants. Not yet recruiting.
25 February 2027
Quick facts
| Lead sponsor | Guangzhou Manjing biomedicine technology co., ltd |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 30 March 2026 |
| Primary completion | 25 February 2027 |
| Estimated completion | 30 June 2027 |
Drugs / interventions tested
- Conventional therapeutic drugs
- NT-88
Conditions studied
- Heart Failure With Mildly Reduced Ejection Fraction — all drugs for Heart Failure With Mildly Reduced Ejection Fraction →
Sponsor
Guangzhou Manjing biomedicine technology co., ltd
Who can join
18 and older, any sex, with Heart Failure With Mildly Reduced Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A study to evaluate the safety and preliminary efficacy of Zuozhu Daxi in patients with chronic heart failure with mildly reduced ejection fraction
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07509801
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure With Mildly Reduced Ejection Fraction
Currently open trials in the same condition.
- NCT07037459 — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity · Phase 3 · recruiting
- NCT06862908 — A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity · Phase 2 · recruiting
- NCT05651919 — PBMC as Biomarkers of Diabetic Cardiomyopathy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07509801 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Manjing biomedicine technology co., ltd
- Last refreshed: 3 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07509801.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing